Discordance between oncotype DX recurrence score and RSPC for predicting residual risk of recurrence in ER-positive breast cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1573-7217
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Discordance between oncotype DX recurrence score and RSPC for predicting residual risk of recurrence in ER-positive breast cancer ; day:11 ; month:11 ; year:2017 ; pages:1-10
Breast cancer research and treatment ; (11.11.2017), 1-10
- Keyword
-
Krebs
Onkologie
- Creator
-
Dodson, Andrew
- Contributor
-
Okonji, David
Assersohn, Laura
Rigg, Anne
Sheri, Amna
Turner, Nick
Smith, Ian
Parton, Marina
Dowsett, Mitch
SpringerLink (Online service)
- DOI
-
10.1007/s10549-017-4514-z
- URN
-
urn:nbn:de:1111-2018011011409
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 5:20 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Dodson, Andrew
- Okonji, David
- Assersohn, Laura
- Rigg, Anne
- Sheri, Amna
- Turner, Nick
- Smith, Ian
- Parton, Marina
- Dowsett, Mitch
- SpringerLink (Online service)
Other Objects (12)
Breast Cancer with Low Recurrence Score on Oncotype DX©: Interplay Between Early Recurrence, Lobular Histology and BRCA Mutation
Oncotype DX Breast Recurrence Score Test : klinische Erfahrungen mit dem genomischen Oncotype DX Breast Recurrence Score Test bei der Entscheidung für oder gegen eine Chemotherapie des frühen, hormonrezeptorpositiven, HER2-negativen Mammakarzinoms
Vergleichende Untersuchung des Oncotype DX Recurrence-Score und Genexpressionstests MammaTyper beim invasiven Mammakarzinom
Vergleich immunhistochemischer Markerprofile Her2/neu negativer, hormonrezeptorpositiver Mammakarzinome mit dem Recurrence-Score des OncotypeDX®.
BCL-2 expression aids in the immunohistochemical prediction of the Oncotype DX breast cancer recurrence score
Oncotype DX breast cancer recurrence score can be predicted with a novel nomogram using clinicopathologic data
Does Mode of Surgical Intervention Based on Oncotype DX Score Influence Disease Recurrence in Early Breast Cancer?
Treatment decisions in estrogen receptor-positive early breast cancer patients with intermediate oncotype DX recurrence score results
Breast cancer subtype discordance: impact on post-recurrence survival and potential treatment options
Two cases of colorectal liver metastasis with residual liver recurrence after a long recurrence-free survival period
Correction to: Breast cancer subtype discordance: impact on post-recurrence survival and potential treatment options
Discordance between Primary Breast Cancer and Ipsilateral Breast Cancer Tumor Recurrence as a Function of Distance
Breast Cancer with Low Recurrence Score on Oncotype DX©: Interplay Between Early Recurrence, Lobular Histology and BRCA Mutation
Oncotype DX Breast Recurrence Score Test : klinische Erfahrungen mit dem genomischen Oncotype DX Breast Recurrence Score Test bei der Entscheidung für oder gegen eine Chemotherapie des frühen, hormonrezeptorpositiven, HER2-negativen Mammakarzinoms
Vergleichende Untersuchung des Oncotype DX Recurrence-Score und Genexpressionstests MammaTyper beim invasiven Mammakarzinom
Vergleich immunhistochemischer Markerprofile Her2/neu negativer, hormonrezeptorpositiver Mammakarzinome mit dem Recurrence-Score des OncotypeDX®.
BCL-2 expression aids in the immunohistochemical prediction of the Oncotype DX breast cancer recurrence score
Oncotype DX breast cancer recurrence score can be predicted with a novel nomogram using clinicopathologic data
Does Mode of Surgical Intervention Based on Oncotype DX Score Influence Disease Recurrence in Early Breast Cancer?
Treatment decisions in estrogen receptor-positive early breast cancer patients with intermediate oncotype DX recurrence score results
Breast cancer subtype discordance: impact on post-recurrence survival and potential treatment options
Two cases of colorectal liver metastasis with residual liver recurrence after a long recurrence-free survival period
Correction to: Breast cancer subtype discordance: impact on post-recurrence survival and potential treatment options
Discordance between Primary Breast Cancer and Ipsilateral Breast Cancer Tumor Recurrence as a Function of Distance
Breast Cancer with Low Recurrence Score on Oncotype DX©: Interplay Between Early Recurrence, Lobular Histology and BRCA Mutation
Oncotype DX Breast Recurrence Score Test : klinische Erfahrungen mit dem genomischen Oncotype DX Breast Recurrence Score Test bei der Entscheidung für oder gegen eine Chemotherapie des frühen, hormonrezeptorpositiven, HER2-negativen Mammakarzinoms
Vergleichende Untersuchung des Oncotype DX Recurrence-Score und Genexpressionstests MammaTyper beim invasiven Mammakarzinom
Vergleich immunhistochemischer Markerprofile Her2/neu negativer, hormonrezeptorpositiver Mammakarzinome mit dem Recurrence-Score des OncotypeDX®.
BCL-2 expression aids in the immunohistochemical prediction of the Oncotype DX breast cancer recurrence score
Oncotype DX breast cancer recurrence score can be predicted with a novel nomogram using clinicopathologic data
Does Mode of Surgical Intervention Based on Oncotype DX Score Influence Disease Recurrence in Early Breast Cancer?
Treatment decisions in estrogen receptor-positive early breast cancer patients with intermediate oncotype DX recurrence score results
Breast cancer subtype discordance: impact on post-recurrence survival and potential treatment options
Two cases of colorectal liver metastasis with residual liver recurrence after a long recurrence-free survival period
Correction to: Breast cancer subtype discordance: impact on post-recurrence survival and potential treatment options